Zepbound for teens has new trial evidence, but its U.S. label still covers adults. A positive study does not change that age limit by itself. For a family, the news adds evidence to discuss with a child's specialist. It does not turn an adult prescription into a teenager's treatment plan.
Zepbound for teens: what the new trial found
As of November 19, 2026, the day this article was written, Aaron Kelly and colleagues' JAMA paper, published November 15, 2026, reports the SURMOUNT-ADOLESCENTS results. The registered study assigned 160 teens ages 12 to under 18 to tirzepatide, Zepbound's active ingredient, or placebo, an inactive injection. Both groups received food and activity counseling.
BMI, or body mass index, measures weight relative to height. After 72 weeks, average BMI fell 18.5% with tirzepatide and rose 0.5% with placebo. About 8 in 10 reached at least a 5% BMI reduction: 79.6% versus 28.5%.
Teenagers are still growing. Height changes affect BMI, so an 18.5% BMI reduction is different from losing 18.5% of body weight. Pounds alone leave out that growth context.
What this means for an adult taking tirzepatide
For a parent already taking tirzepatide, these findings describe another age group. They do not supply a new adult dose or a reason to change an existing prescription.
An adult's own treatment discussion still starts with their health history, goals, other medicines and side effects. A child's treatment discussion needs a clinician who follows that child's growth. Those conversations can happen in the same family without sharing a prescription or a dosing plan.
Why the headlines say both 18.5% and 21.4%
Lilly's November 14, 2026 announcement highlighted a 21.4% BMI reduction and said more than half no longer met the BMI definition of obesity. A JAMA editor's note explains why two averages appear.
The 18.5% result includes treatment stops. The 21.4% result models what would happen if everyone continued assigned treatment. Missing measurements require estimates; the larger figure is not simply an average of people who finished.
An estimand is the exact treatment question behind an estimate. Both calculations used the 159 participants who received a dose; one teen withdrew before starting. Neither percentage predicts one teenager's result.
Side effects and the limits of 72 weeks
Stomach and bowel problems were most common and mostly mild or moderate. Adverse events are health problems recorded during a study; recording one does not prove the medicine caused it.
Serious events include problems requiring hospital care. The paper's safety table reports:
| Recorded outcome | Tirzepatide, 108 teens | Placebo, 51 teens |
|---|---|---|
| Stomach or bowel events | 81.5% | 54.9% |
| Stopped treatment because of adverse events | 10 teens, 9.3% | 0 |
| Serious adverse events | 7.4% | 3.9% |
Depression or suicidal thoughts were recorded as adverse events in 5 tirzepatide-treated teens (4.6%) and 1 placebo-treated teen (2.0%); none was a serious adverse event. Because teens with obesity are more likely to have major depression, the authors call for vigilant monitoring.
Growth and puberty measures were similar between groups during the trial. Many teens had already finished puberty, limiting conclusions about earlier development. A small trial cannot settle uncommon harms or lifelong safety. Four weeks of safety follow-up after treatment cannot establish years of outcomes after stopping. Lilly funded the trial and helped design and analyze it.
Semaglutide already has separate adolescent evidence
The 2022 STEP TEENS paper in the New England Journal of Medicine studied 201 adolescents for 68 weeks. Average BMI fell 16.1% with semaglutide and rose 0.6% with placebo, alongside lifestyle support. The STEP TEENS results guide covers its safety findings and limits.
These were separate trials with different participants and durations. Comparing their headline percentages cannot establish which medicine is better for teens. Research in younger children is another question again.
For adults comparing semaglutide and tirzepatide
A parent considering semaglutide for themselves needs an adult assessment. The choice between semaglutide and tirzepatide depends on that person's treatment goal, medical history and tolerance of side effects.
Semaglutide acts on GLP-1, a gut hormone signal involved in fullness and blood sugar. Tirzepatide also acts on GIP, another gut hormone signal. That difference in how they work does not make either one the right choice for every adult.
Trial evidence does not rewrite the age limits
As of November 19, 2026, the day this article was written, the Zepbound FDA label says “Revised: 08/2026.” Its uses are for adults; section 8.4 says safety and effectiveness have not been established in children. The trial has not expanded its labeled use to anyone under 18.
The Wegovy label, “Revised: 06/2026,” covers injections for obesity from age 12. The Mounjaro label, “Revised: 08/2026,” covers blood-sugar control in type 2 diabetes from age 10. Type 2 diabetes is a condition in which blood sugar stays too high. That diabetes use does not establish a teen weight-management use for Zepbound.
An adult compounded prescription has its own review
Tirzepatide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounding means a pharmacy prepares medication for a prescription. FDA explains that it does not review compounded drugs for safety, effectiveness or quality before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor.
The teen trial did not test a compounded preparation. Its findings do not establish results for one. A prescriber sets the actual dose and follow-up plan for an adult prescription.
As of November 19, 2026, the day this article was written, FDA's November 9, 2026 safety communication also requires new information about eye risks for GLP-1 medicines, including Zepbound. It concerns NAION, injury from reduced blood flow to the nerve carrying sight signals. It can cause permanent sight loss. FDA says sudden painless sight loss, missing or blurred patches, distorted colors or reduced central sharpness require contact with a health care professional right away.
What to watch next
The useful next questions are whether the label's section on children changes and what longer follow-up shows. Larger studies are also needed to assess uncommon harms. Access is a separate problem, covered in the teen obesity treatment gap guide.
Promise's prescriber network treats adults 18 and older. Treatment for anyone younger is a decision for the child's own pediatrician or a pediatric obesity specialist, a doctor who treats children's weight-related health problems.
At Promise, a licensed provider reviews every request, and not everyone qualifies.





